March 21, 2024
The Honorable James Lankford
Senator from Oklahoma
316 Hart Senate Office Building
Washington, DC 20510
Dear Senator Lankford,
On behalf of the 2.1 million members of AMAC – the Association of Mature American Citizens, including nearly 32,000 residing in Oklahoma, I am pleased to offer our support for the Ensuring Access to Lower-Cost Medicines for Seniors Act, S. 2129. This legislation aims to provide much-needed relief to our nation’s seniors by ensuring access to affordable prescription medications.
Seniors are facing an unprecedented challenge in accessing affordable prescription drugs. Many mature Americans are on fixed incomes and are forced to make difficult choices between purchasing essential medications or meeting other basic needs. S. 2129 addresses this urgent issue by implementing much needed reforms to lower the cost of prescription drugs for seniors.
The Ensuring Access to Lower-Cost Medicines for Seniors Act includes measures to increase transparency in drug pricing and promote the use of generic medications. Expanding Medicare Part D to include coverage for generic and biosimilar drugs is a critical step in promoting affordability, accessibility, and innovation in the pharmaceutical landscape. Generic drugs offer cost-effective alternatives to brand-name medications, allowing seniors to access essential treatments at significantly lower prices. By ensuring coverage for generics and biosimilars, Medicare Part D can help seniors save on out-of-pocket expenses, alleviate financial burdens, and improve medication adherence.
Additionally, fostering the utilization of biosimilar drugs encourages competition, driving down prices and promoting innovation in the pharmaceutical industry. Overall, incorporating generic and biosimilar drugs into Medicare Part D not only benefits seniors by providing them with more affordable options but also contributes to a more sustainable and efficient healthcare system for all beneficiaries.
This bipartisan legislation represents a critical step towards addressing the high cost of prescription drugs and ensuring that seniors can access the medications that they need to maintain their health and well-being. Thank you, Senator Lankford, for introducing this critical piece of legislation.
Sincerely,
Bob Carlstrom
President
AMAC Action
We hope you've enjoyed this article. While you're here, we have a small favor to ask...
Support AMAC Action. Our 501 (C)(4) advances initiatives on Capitol Hill, in the state legislatures, and at the local level to protect American values, free speech, the exercise of religion, equality of opportunity, sanctity of life, and the rule of law.
Donate Now
Copyright © 2024 AMAC, Inc. / AMAC Senior Resources Network. All rights reserved.
In committing mass, pre-meditated murder, rape, torture, kidnapping, false imprisonment and other atrocities, Hamas has demonstrated that they are unworthy of living in any civilized country. They need to remove themselves from civilization.
Likewise, the Biden Administration and its supporting legislators and citizens should also look for another country, besides ours, to live in. Supporting murderers for the purpose of buying votes is not leadership. It is depravity.
As both a senior citizen and a long-time project engineer/project manager on pharmaceutical design and construction projects, I have seen enough to hope that any drug price reduction legislation does not ignore the costs of research and manufacturing.
Pharmaceutical operations require enormous budgets to keep the facilities viable, FDA-compliant, safe to work in, and capable of producing high-quality, life-saving medications that many depend upon. The costs of operating and ongoing renovations/process revisions in these research and manufacturing plants – in the face of ever-changing regulatory and competitive conditions – are “formidable”, to say the least.
Most people have no idea, and I find it offensive that these vital manufacturing plants are being blamed for the cost of saving lives, while the regulators seem to shoulder very little of that burden.
I have always felt that the FDA should be challenged with justifying the anticipated cost impacts of any new directives. These revisions should not be made just to make the regulator “look engaged”.
Add
Organic RX
Herbal RX
Supplements OTC to Help